Last reviewed · How we verify
Physiologic Effects of Long-Term GHRH1-44 in Abdominal Obesity
Obesity, a condition that occurs when a person has too much body fat, affects about 31% of people in the United States. It is associated with increased risk of diabetes, high blood pressure, high cholesterol, and cardiovascular disease. Abdominal obesity, in particular, is also associated with low levels of growth hormone, a hormone that affects rate of growth and the way the body uses energy. Growth hormone releasing hormone (GHRH) is a substance that makes the body naturally increase its own growth hormone levels. Administering GHRH to people who are obese may help return their growth hormone levels to normal and, in turn, may lead to reduced abdominal fat and improved cardiovascular function. This study will evaluate the effectiveness of synthetic GHRH in decreasing the amount of abdominal fat and improving cardiovascular function in people who are obese.
Details
| Lead sponsor | Massachusetts General Hospital |
|---|---|
| Phase | Phase 2 |
| Status | COMPLETED |
| Enrolment | 60 |
| Start date | 2008-07 |
| Completion | 2012-01 |
Conditions
- Abdominal Obesity
- Growth Hormone Deficiency
Interventions
- Growth hormone releasing hormone (GHRH) 1-44
- Placebo
Primary outcomes
- Change in Visceral Adipose Tissue Volume — Measured at baseline and Months 6 and 12
Abdominal visceral adipose tissue and subcutaneous adipose tissue were assessed using a single crosssectional slice from noncontrast computed tomography at the L4 level. The change in abdominal visceral adiposity between baseline and twelve months is reported.
Countries
United States